Access Pharmaceuticals (ACCP) Provides Update on MuGard Commercial Launch in North America
11/11/2009 10:38:03 AM
More...
|
Access Pharmaceuticals (ACCP) Provides Update on MuGard Commercial Launch and First European Clinicians Feedback European Launch On Target
10/15/2009 9:09:07 AM
More...
|
Access Pharmaceuticals (ACCP) Signs eMarketing Agreement With iMedicor
10/6/2009 9:35:59 AM
More...
|
Access Pharmaceuticals (ACCP) Provides Update on ProLindac(TM)Clinical Development Plan
9/11/2009 10:08:25 AM
More...
|
Access Pharmaceuticals (ACCP) Signs Agreement to Manufacture Its FDA-Approved MuGard in the United States
9/11/2009 10:06:54 AM
More...
|
Access Pharmaceuticals (ACCP) CEO Interviewed on CorporateProfile.com
9/1/2009 11:20:47 AM
More...
|
Access Pharmaceuticals (ACCP) Provides Update on ProLindac Clinical Development Program Enrolling Ovarian Cancer Patients in France; Finalizing Clinical Trial Programs with Partners in China and Korea
8/3/2009 9:51:49 AM
More...
|
Access Pharmaceuticals (ACCP) Announces New MuGard Commercial Strategy in North America
7/29/2009 8:32:06 AM
More...
|
Access Pharmaceuticals (ACCP) Announces Commercial Launch of MuGard(TM) in Norway by SpePharm
7/27/2009 9:05:01 AM
More...
|
Access Pharmaceuticals (ACCP) Release: MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients
7/23/2009 8:50:32 AM
More...
|
|